| part | subject | predicate | object | published by | date | |
|---|---|---|---|---|---|---|
|
Assertion
|
|
|||||
|
Assertion
|
The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain.
|
|
||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|